Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors.[1] It was discovered and developed by Taiho Pharmaceutical Co.[2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90).[3]
In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy.[4]
^"Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)" (Press release). Taiho Pharmaceutical. June 20, 2022.
^Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. (June 2022). "Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial". Annals of Oncology. 33 (9): 959–967. doi:10.1016/j.annonc.2022.05.518. PMID 35688358. S2CID 249532381.
^Hoy SM (August 2022). "Pimitespib: First Approval". Drugs. 82 (13): 1413–1418. doi:10.1007/s40265-022-01764-6. PMID 35986838. S2CID 251672805.
Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors. It was discovered and developed by Taiho Pharmaceutical...
cells. In June 2022 pimitespib received its first approval in Japan for GIST that has progressed after chemotherapy. Pimitespib is an oral small molecule...